Stefan K. Barta

Dr. Stefan K. Barta is a Clinical Associate Professor of Medicine in the Department of Hematology-Oncology at the Perelman School of Medicine, University of Pennsylvania. He directs the T-Cell Lymphoma Program at Abramson Cancer Center and serves as Executive Officer of the National Cancer Institute-funded AIDS Malignancy Consortium.

His medical training spans international institutions:

• Medical Degree: Johann Wolfgang Goethe University
• Residencies: Whipps Cross University Hospital, Burnley General Teaching Hospital, The Whittington Hospital, St. Bartholomew's and The Royal London Hospital, Mount Sinai Morningside
• Fellowships: St. Bartholomew's and The Royal London Hospital, Montefiore Medical Center

Dr. Barta's research centers on high-risk lymphomas, with dual expertise in T-cell malignancies and CNS lymphoma. His work bridges genomic analysis (notably next-generation sequencing applications) with clinical trial development, focusing on optimizing CAR T-cell therapy for refractory cases and managing lymphomas in immunocompromised populations. The T-Cell Lymphoma Program under his direction provides specialized diagnostics and novel treatment protocols for rare lymphoma subtypes.

His 2025 publications demonstrate consistent output in high-impact journals, with themes emphasizing real-world CAR T-cell outcomes, CNS involvement risk stratification, and genomic-guided therapy. Key contributions include establishing MTR-based regimens for CNS lymphoma and defining neurotoxicity management protocols.

As Executive Officer of the AIDS Malignancy Consortium, Dr. Barta oversees a major NCI-funded network advancing HIV-associated cancer research. His clinical practice at the Perelman Center maintains exceptional patient satisfaction (5.0/5.0 from 683 reviews), reflecting his dual commitment to innovative research and personalized patient care in complex lymphoma cases.